Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs TJX Companies Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $357.58 (market cap $9.43B), while TJX Companies Inc trades at $153.61 (market cap $172.05B). The key difference: TJX Companies Inc is far larger — about 18.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and TJX Companies Inc pays a 1.23% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | TJX | |
|---|---|---|
Market Cap | $9.43B | $172.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $168.41 |
52-Week Low | $241.71 | $132.62 |
Enterprise Value | $9.18B | $180.65B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
TJX trades at $154.17, down 2.92% over the past day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.19 exceeding the $1.02 estimate. Revenue grew to $56.36 billion in 2025, and net income margin improved to 8.63%. Analysts maintain a bullish consensus with an average price target of $181.80, citing momentum and value prospects.
The outlook for TJX remains positive driven by consistent earnings outperformance and robust profitability metrics like a 61.25% ROE. Key risks include competitive pressures in discount retail and sensitivity to consumer spending trends. The stock offers upside to analyst targets but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
